3.66
price up icon11.93%   0.39
after-market After Hours: 3.74 0.08 +2.19%
loading
Affimed N V stock is traded at $3.66, with a volume of 196.27K. It is up +11.93% in the last 24 hours and up +14.02% over the past month. Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
See More
Previous Close:
$3.27
Open:
$3.24
24h Volume:
196.27K
Relative Volume:
2.45
Market Cap:
$51.59M
Revenue:
$19.91M
Net Income/Loss:
$-127.11M
P/E Ratio:
-4.6959
EPS:
-0.7794
Net Cash Flow:
$-132.44M
1W Performance:
+9.25%
1M Performance:
+14.02%
6M Performance:
-32.47%
1Y Performance:
+0.33%
1-Day Range:
Value
$3.24
$3.7199
1-Week Range:
Value
$3.159
$3.7199
52-Week Range:
Value
$2.9178
$8.95

Affimed N V Stock (AFMD) Company Profile

Name
Name
Affimed N V
Name
Phone
-
Name
Address
-
Name
Employee
78
Name
Twitter
@affimed
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
AFMD's Discussions on Twitter

Affimed N V Stock (AFMD) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-12-22 Initiated H.C. Wainwright Buy
Oct-10-22 Downgrade Stifel Buy → Hold
Aug-18-22 Resumed Wells Fargo Overweight
Mar-31-22 Initiated Piper Sandler Overweight
Feb-23-22 Initiated Cantor Fitzgerald Overweight
Oct-21-21 Initiated Truist Buy
Sep-30-21 Initiated Stifel Buy
Mar-31-21 Initiated Credit Suisse Outperform
Mar-28-19 Initiated SVB Leerink Outperform
Aug-28-18 Upgrade Jefferies Hold → Buy
Jul-14-17 Initiated SunTrust Buy
Aug-12-16 Downgrade Leerink Partners Outperform → Mkt Perform
May-19-16 Downgrade Leerink Partners Outperform → Mkt Perform
Dec-10-15 Initiated Laidlaw Buy
Dec-04-15 Initiated Wells Fargo Outperform
Sep-09-15 Initiated Jefferies Hold
Aug-06-15 Reiterated Oppenheimer Outperform
Jun-22-15 Reiterated Jefferies Buy
View All

Affimed N V Stock (AFMD) Latest News

pulisher
09:17 AM

Affimed Announces Acceptance of Three Abstracts at the 2024 - GlobeNewswire

09:17 AM
pulisher
09:00 AM

Affimed N.V. Announces Acceptance of Three Abstracts At the 2024 Ash Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma - Marketscreener.com

09:00 AM
pulisher
Oct 28, 2024

Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Affimed (NASDAQ:AFMD) Given Average Rating of “Buy” by Analysts - Defense World

Oct 28, 2024
pulisher
Oct 27, 2024

Affimed (NASDAQ:AFMD) Short Interest Update - MarketBeat

Oct 27, 2024
pulisher
Oct 24, 2024

683 Capital Management, LLC Expands Stake in Affimed NV - Yahoo Finance

Oct 24, 2024
pulisher
Oct 15, 2024

Affimed Appoints New Director Amid Strategic Moves - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

Affimed N : Annual General Meeting Results Form 6 K - Marketscreener.com

Oct 15, 2024
pulisher
Oct 04, 2024

Affimed N : Presentation - Marketscreener.com

Oct 04, 2024
pulisher
Oct 03, 2024

Analysts Set Affimed (NASDAQ:AFMD) Target Price at $20.00 - MarketBeat

Oct 03, 2024
pulisher
Sep 30, 2024

Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN

Sep 30, 2024
pulisher
Sep 21, 2024

Affimed appoints Shawn Leland as chief executive officer - MSN

Sep 21, 2024
pulisher
Sep 17, 2024

Affimed (NASDAQ:AFMD) Sees Significant Decrease in Short Interest - MarketBeat

Sep 17, 2024
pulisher
Sep 13, 2024

AFMDAffimed N.V. Latest Stock News & Market Updates - StockTitan

Sep 13, 2024
pulisher
Sep 12, 2024

Affimed N.V. Announces Upcoming EGM - TipRanks

Sep 12, 2024
pulisher
Sep 10, 2024

Affimed to Present at the Cantor Global Healthcare Conference 2024 - GlobeNewswire

Sep 10, 2024
pulisher
Sep 10, 2024

Affimed (NASDAQ:AFMD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World

Sep 10, 2024
pulisher
Sep 09, 2024

Cantor Fitzgerald Reiterates "Overweight" Rating for Affimed (NASDAQ:AFMD) - MarketBeat

Sep 09, 2024
pulisher
Sep 08, 2024

Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Sep 08, 2024
pulisher
Sep 07, 2024

Affimed N.V. (NASDAQ:AFMD) Q2 2024 Earnings Call Transcript - Insider Monkey

Sep 07, 2024
pulisher
Sep 06, 2024

HC Wainwright Reaffirms Buy Rating for Affimed (NASDAQ:AFMD) - MarketBeat

Sep 06, 2024
pulisher
Sep 06, 2024

Earnings call: Affimed reports promising clinical results and stable finances By Investing.com - Investing.com Australia

Sep 06, 2024
pulisher
Sep 06, 2024

Earnings call: Affimed reports promising clinical results and stable finances - Investing.com

Sep 06, 2024
pulisher
Sep 06, 2024

Affimed NV (AFMD) Q2 2024 Earnings Call Transcript Highlights: F - GuruFocus.com

Sep 06, 2024
pulisher
Sep 06, 2024

Affimed N.V.: Q2 Earnings Snapshot - New Haven Register

Sep 06, 2024
pulisher
Sep 05, 2024

Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 05, 2024

Stifel holds Affimed at $5 target with new CEO at helm By Investing.com - Investing.com Canada

Sep 05, 2024
pulisher
Sep 05, 2024

Stifel holds Affimed at $5 target with new CEO at helm - Investing.com

Sep 05, 2024
pulisher
Sep 05, 2024

Affimed Appoints Shawn M. Leland as Chief Executive Officer - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 05, 2024

Affimed Reports Second Quarter 2024 Financial Results & Business Update - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 05, 2024

Affimed NV reports results for the quarter ended in June 30Earnings Summary - xm.com

Sep 05, 2024
pulisher
Sep 05, 2024

Affimed reports Q2 EPS (EUR1.01) vs. (EUR1.97) last year - TipRanks

Sep 05, 2024
pulisher
Sep 05, 2024

Affimed N.V. Faces Substantial Mid-Year Losses - TipRanks

Sep 05, 2024
pulisher
Sep 05, 2024

Affimed N.V.: Q2 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria

Sep 05, 2024
pulisher
Sep 04, 2024

Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts - Seeking Alpha

Sep 04, 2024
pulisher
Sep 04, 2024

Affimed NV (AFMD) Q2 2024 Earnings Report Preview: What To Look For - GuruFocus.com

Sep 04, 2024
pulisher
Sep 03, 2024

Affimed names Shawn Leland as new CEO By Investing.com - Investing.com Canada

Sep 03, 2024
pulisher
Sep 03, 2024

Affimed appoints Shawn Leland as Chief Executive Officer - TipRanks

Sep 03, 2024
pulisher
Sep 03, 2024

Affimed Appoints New CEO to Bolster Growth - TipRanks

Sep 03, 2024
pulisher
Sep 03, 2024

Affimed names Shawn Leland as new CEO - Investing.com

Sep 03, 2024
pulisher
Aug 30, 2024

Affimed (AFMD) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Aug 30, 2024
pulisher
Aug 29, 2024

Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024 - GlobeNewswire

Aug 29, 2024
pulisher
Aug 24, 2024

Affimed (NASDAQ:AFMD) Stock Price Crosses Below 200 Day Moving Average of $5.35 - Defense World

Aug 24, 2024
pulisher
Aug 24, 2024

Affimed (NASDAQ:AFMD) Stock Crosses Below 200 Day Moving Average of $5.35 - MarketBeat

Aug 24, 2024

Affimed N V Stock (AFMD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):